 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||| BPX-603 / Bellicum
Trial suspension, CAR T-Cell Therapy, Metastases: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov) - Apr 20, 2023
P1/2, N=220, Suspended, Sponsor: Bellicum Pharmaceuticals
Recruiting --> Suspended
- || BPX-603 / Bellicum
Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Metastases: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov) - Aug 12, 2022
P1/2, N=220, Recruiting, Sponsor: Bellicum Pharmaceuticals
Recruiting --> Suspended Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
- || molecular iodine2 (BPX-03) / BioPharmX, BPX-601 / Bellicum, BPX-603 / Bellicum
Clinical: Adam or Jacob any thoughts on $BLCM BPX601 PSCA dose escalated/ expansion to prostate CA PTs BPX603 HER2 pts enrolled could we see PR CR? MC 24m institutional ownership has gone up significantly in past qtr. Thanks (Twitter) - Mar 15, 2021
- || molecular iodine2 (BPX-03) / BioPharmX, BPX-603 / Bellicum
Clinical: Institutional investors know @BellicumPharma exists Ikarian Capital Boxer Capital BakerBrothers and TBA hedgfunds own 80% of company in matter of 4 months smart money has been accumulating $BLCM anticipating merger & BPX603 HER2 data in coming months PT $50 on merger $120 on CR (Twitter) - Mar 5, 2021
- ||||| BPX-603 / Bellicum
New P1/2 trial, CAR T-Cell Therapy, Metastases: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov) - Dec 1, 2020
P1/2, N=220, Recruiting, Sponsor: Bellicum Pharmaceuticals